L.C. Steggink

research physician


  1. High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study, Proffered paper (oral presentation) 187O

    Steenbruggen, T. G., Steggink, L., Seynaeve, C. M., van der Hoeven, JJM., Hooning, M. J., Jager, A., Konings, IR., Kroep, J. R., Smit, WM., Tjan-Heijnen, V. C. G., van der Wall, E., Bins, AD., Linn, SC., Schaapveld, M., van Leeuwen, FE., Schroder, C., van Tinteren, H., de Vries, E. G. E., Sonke, G. S. & Gietema, J. A., 2018.

    Research output: Contribution to conferenceAbstractAcademic

  2. Life expectancy 20 years after cisplatin-based treatment for testicular cancer (TC).

    Lubberts, S., Kruyt, L., Steggink, L., Steursma, G., Nuver, J., Oosting, S. F., van Ginkel, R., de Jong, I., Eulenburg, C., Lefrandt, J., Meijer, C., Sluiter, W. J. & Gietema, J. A., May-2017, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35, 5_suppl, p. 4550 1 p., 4550.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (8) »

View graph of relations

ID: 503168